# An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of A Controlled Release Pregabalin Tablet As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule

> **NCT01202435** · PHASE1 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Pregabalin controlled release, 82.5 mg
- **DRUG:** Pregabalin immediate release, 25 mg

## Key facts

- **NCT ID:** NCT01202435
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01202435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01202435, "An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of A Controlled Release Pregabalin Tablet As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01202435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*